


## Europass Curriculum Vitae

### Personal information

First name(s) / Surname(s)



**Annarita Meneguz** 



# Occupational field Work experience

Dates

Occupation or position held

# Farmacotoxicological Research and Evaluation

1998 -date

Head of the Unit of Biochemical Pharmacology and Technical Scientific Advice Coordination Unit Department of Drug Research and Evaluation Istituto Superiore di Sanità (*The Italian National Institute of Health/Governmental*)

Main activities and responsibilities

As the head of one of the Drug research and Evaluation Department involved in centralised, decentralised and Mutual recognition procedure (dossier evaluation Module IV) and control (biological test: abnormal toxicity. Histamine release, Hypotension induction, according to EUP), the main responsibility is to assure that all these activities are performed according to the AQ unit procedure of the Department. Moreover as a member of the Scientific Secretary of the Italian Competent authority form Phase I Clinical Trial authorization I am in charge of Rapportership of anticancer and monoclonal antibody Investigational medicinal product dossier (IMPD).

The main activities and responsibilities can be summarised as follows:

- Budget and human resources management;
- Interaction with the Italian Agency for Medicines (AIFA)
- Signature of all assessment of Module IV of the Department
- Signature of the biological test results (certificate)
- Responsibility of the transmission outside the Institute [mainly to the Osservatorio Nazionale sulla Sperimentazione Clinica con i Medicinali OsSC -(National Monitoring Centre on Clinical Research with Medicines) at the AIFA.

Furthermore, the following activities and positions should be considered (in brackets date since when the position is held. All these positions are still hold.

- Italian Member of Safety Working Party of the Committee for Proprietary Medicinal Products (CHMP), European Medicines Agency (form 1998 see below).
- Italian Member of OECD GL Working Group from 2010
- Italian expert for OECD for Human Health effect (form 1994)
- Expert of the Italian Working Party on Radiopharmaceuticals (from 2008).
- Junior GLP inspector (from 1992 to 1998)
- Senior/Coordinator GLP Inspector (from 1999-2010)
- Expert GMP Inspection only for radiopharmaceuticals (form 2005)

Name and address of employer Type of business or sector Istituto Superiore di Sanità - Viale R. Elena 299 - 00161 - Roma Italian National Public Health Institute

Dates

1979-1998

Occupation or position held

Research Scientist in the Pharmacology Department Istituto Superiore di Sanità

Main activities and responsibilities

Research fields Neurotoxicity and Cyp 450 Metabolism

Name and address of employer

Type of business or sector

Istituto Superiore di Sanità - Viale R. Elena 299 - 00161 - Roma
Italian National Public Health Institute – Italian Official Medicines Control Laboratory

**Dates** 

1998-date

Occupation or position held

Head of Unit of Preclinical Assessment and Phase I Clinical Trials
Department of Drug Research and Evaluation of Istituto Superiore di Sanità
GLP inspection activities within the Istituto Superiore di Sanità and Ministero della Salute
(Ministry of Health)

Main activities and responsibilities

Italian Member of OECD GLP Working Group

Handling of the GLP inspection requests by Ministry of Health

Performing GLP inspections (reports)

GLP Training of observers and junior inspectors

Participation in the national and international (OECD) GLP activities

Phase I IMPD dossier evaluation Radiopharmaceutical expert

Name and address of employer

Drug Research and Evaluation Department, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Roma, Italy

Type of business or sector

Italian National Public Health Institute

## **Education and training**

1974 Dates

Title of qualification awarded

Degree in Bilogical Science

Principal subjects/occupational skills covered Thesis and research on biochemical of fat acids

Name and type of organisation providing education and training

University "La Sapienza", Roma, Italy

# Personal skills and competences

Mother tongue(s)

Italian

## Other language(s)

English

Self-assessment European level (\*)

	lish
⊢ทก	IIen
∟нч	пэп

Understanding				Speaking				1	Writing
	Listening		Reading		Spoken interaction		Spoken production		
B 1		B 2		B 2		B 2		C 1	

<sup>(\*)</sup> Common European Framework of Reference for Languages

Organisational skills and competences Competences in the management of a Department Unit, Coordination of working groups.

Technical skills and competences

Competent in biochemical and enzymatic techniques suitable for investigate neurotoxicity and drug metabolis.

Computer skills and competences

good command of Microsoft Office™ tools (Word™, Excel™ and PowerPoint™) for Windows PC

Other skills and competences

Reviewer for Italian Toxicological Society journal

Participation to national and European project research projects

#### Additional information

Research Interest

- Toxixity/Neurotoxicity
- Metabolism

Main Scientific publications (2005-2010)

- Meneguz A. Valutazione preclinica dei vaccini. In: Cantelli Forti G, Hrelia P, ed. Le biotecnologie e la qualità della vita. Bologna: Patron editore; 2005. p. 103-128.
- Gribaldo L, Gennari A, Blackburn H, Clemedson C, Deguercy A, Meneguz A, Pfaller W, Ruhdel I. Acute toxicity. Alternatives to laboratory animals: ATLA. 2005;33(Suppl 1):27-34.
- 3. Prieto P, Clemedson C, **Meneguz A**, Pfaller W, Sauer UG, Westmoreland C. Subacute and subchronic toxicity. *Alternatives to laboratory animals: ATLA*. 2005;33(Suppl 1):109-116.
- Coecke S, Blaauboer B, Elaut G, Freeman S, Freidig A, Gensmantel N, Hoet P, Kapoulas VM, Ladstetter B, Langley G, Leahy D, Mannens G, Meneguz A, Monshouwer M, Nemery B, Pelkonen O, Pfaller W, Prieto P, Proctor N, Rogiers V, Rostami-Hodjegan A, Sabbioni E, Steiling W, van de Sandt JJ. Toxicokinetics and metabolism. Alternatives to laboratory animals: ATLA. 2005:33(Suppl 1):147-175.
- Cometa MF, Lorenzini P, Fortuna S, Volpe MT, Meneguz A, Palmery M. In vitro inhibitory effect of aflatoxin B1 on acetylcholinesterase activity in mouse brain. *Toxicology*. 2005;206(1):125-135.
- Buratti FM, D'Aniello A, Volpe MT, Meneguz A, Testai E. Malathion bioactivation in the human liver: the contribution of different cytochrome P450 isoforms. *Drug metabolism and disposition*. 2005;33(3):295-302.
- 7. Di Consiglio E, **Meneguz A**, and Testai E. Organophosphorotionate pesticides inhibit bioactivation of imipramine by human hepatic cytochrome P450s Tox. Appl. Pharmaco, 2005; 15, 237-246.
- 8. Coecke S, Ahr H, Blaauboer B, Bremer S, Casati S, Castell J, Combes R, et al., **Meneguz A**, Testai E. Metabolism: a bottleneck in in vitro toxicological test development. The report and recommendations of ECVAM workshop 54. *Alternatives to laboratory animals: ATLA*. 2006; 34(1):49-84.
- Cholinesterase inhibition and alterations of hepatic metabolism by oral acute and repeated chlorpyrifos administration to mice. Cometa MF, Buratti FM, Fortuna S, Lorenzini P, Volpe MT, Parisi L, Testai E, Meneguz A Toxicology. 2007 Feb 23.

### Capitolo di Libri

- Autorità regolatorie e processo registrativo di nuovi farmaci antineoplastici (Stefano Vella, Annarita Meneguz).in Sviluppo dei farmaci oncologici con bersaglio molecolare: dalla tradizione all'innovazione (a cura di Dino Amadori). Paletto editore. 2007
- A. Meneguz Valutazione preclinica dei vaccini. Biotecnologie e qualità della vita. A cura di G. Cantelli forti e P. Hrelia . Patron editore 2005.
- Advanced Therapy: rules and experiences of the Phase I Italian Competent Authority.
   Annarita Meneguz, Dipartimento del Farmaco ISS, Pharmaceuticals Policy and Law, 2014
- A. Meneguz, MF Cometa Verso una revisione della Direttiva 2001/20 e una maggiore armonizzazione europea dei trial clinici precoci. In .Rapporti ISTISAN: 12/37Attività e impegno dell'Istituto Superiore di Sanità nella lotta contro il cancro. 2014

#### Libri

Sperimentazione e registrazione dei radio farmaci Normative e procedure Springer ED 2013, A cura di Lucignani, Nicotra e Meneguz Evaluation Activity

- Number of Non Clinical Assessment Report for European procedures (Centralised, decentralised, Mutual Recognition): 250
- Number of IMPD Phase 1 assessment: 350
- Number of GLP inspection: > 70
- Radiopharmaceutical Assessment Report: 32 (CHMP Core Procedure), 10 new procedure

Rome, 03/03/2015

Signature
Dr. Annarita Meneguz